25 XP   0   0   10

Medexus Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Medexus together

PenkeI guess you are interested in Medexus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Medexus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Medexus Pharmaceuticals Inc

I send you an email if I find something interesting about Medexus Pharmaceuticals Inc.

Quick analysis of Medexus (30 sec.)










What can you expect buying and holding a share of Medexus? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$1.66
Expected worth in 1 year
C$2.46
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
C$0.80
Return On Investment
51.3%

For what price can you sell your share?

Current Price per Share
C$1.55
Expected price per share
C$1.44 - C$2.28
How sure are you?
50%

1. Valuation of Medexus (5 min.)




Live pricePrice per Share (EOD)

C$1.55

Intrinsic Value Per Share

C$0.76 - C$0.91

Total Value Per Share

C$2.42 - C$2.57

2. Growth of Medexus (5 min.)




Is Medexus growing?

Current yearPrevious yearGrowGrow %
How rich?$29.5m$16.9m$7.1m29.8%

How much money is Medexus making?

Current yearPrevious yearGrowGrow %
Making money$1.4m-$2.7m$4.1m285.7%
Net Profit Margin5.1%-11.8%--

How much money comes from the company's main activities?

3. Financial Health of Medexus (5 min.)




What can you expect buying and holding a share of Medexus? (5 min.)

Welcome investor! Medexus's management wants to use your money to grow the business. In return you get a share of Medexus.

What can you expect buying and holding a share of Medexus?

First you should know what it really means to hold a share of Medexus. And how you can make/lose money.

Speculation

The Price per Share of Medexus is C$1.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Medexus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Medexus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$1.66. Based on the TTM, the Book Value Change Per Share is C$0.20 per quarter. Based on the YOY, the Book Value Change Per Share is C$-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Medexus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps-0.02-1.4%0.063.9%-0.11-7.2%-0.10-6.2%-0.10-6.2%
Usd Book Value Change Per Share0.3220.6%0.149.3%-0.08-5.1%0.084.9%0.084.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.3220.6%0.149.3%-0.08-5.1%0.084.9%0.084.9%
Usd Price Per Share1.79-1.63-1.48-2.49-2.49-
Price to Earnings Ratio-20.55--4.80--4.14--4.50--4.50-
Price-to-Total Gains Ratio5.61-18.29--53.64--16.51--16.51-
Price to Book Ratio1.48-1.67-2.13-4.73-4.73-
Price-to-Total Gains Ratio5.61-18.29--53.64--16.51--16.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.12592
Number of shares888
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.140.08
Usd Total Gains Per Share0.140.08
Gains per Quarter (888 shares)128.2767.07
Gains per Year (888 shares)513.07268.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105135030268258
20102610160537526
30153915290805794
4020522042010731062
5025652555013411330
6030783068016101598
7035913581018781866
8041054094021462134
9046184607024142402
10051315120026832670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%3.013.00.018.8%3.013.00.018.8%3.013.00.018.8%
Book Value Change Per Share3.01.00.075.0%5.07.00.041.7%6.010.00.037.5%6.010.00.037.5%6.010.00.037.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share3.01.00.075.0%5.07.00.041.7%6.010.00.037.5%6.010.00.037.5%6.010.00.037.5%

Fundamentals of Medexus

About Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Fundamental data was last updated by Penke on 2024-04-04 18:38:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Medexus Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Medexus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -2.1% means that $-0.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Medexus Pharmaceuticals Inc:

  • The MRQ is -2.1%. The company is making a loss. -1
  • The TTM is 5.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM5.1%-7.2%
TTM5.1%YOY-11.8%+16.9%
TTM5.1%5Y-10.4%+15.5%
5Y-10.4%10Y-10.4%0.0%
1.1.2. Return on Assets

Shows how efficient Medexus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.3% Return on Assets means that Medexus generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Medexus Pharmaceuticals Inc:

  • The MRQ is -0.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.9%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.3%TTM0.9%-1.2%
TTM0.9%YOY-1.9%+2.9%
TTM0.9%5Y-1.5%+2.4%
5Y-1.5%10Y-1.5%0.0%
1.1.3. Return on Equity

Shows how efficient Medexus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.8% Return on Equity means Medexus generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Medexus Pharmaceuticals Inc:

  • The MRQ is -1.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 6.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-1.8%TTM6.6%-8.4%
TTM6.6%YOY-15.9%+22.5%
TTM6.6%5Y-28.4%+35.1%
5Y-28.4%10Y-28.4%0.0%

1.2. Operating Efficiency of Medexus Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Medexus is operating .

  • Measures how much profit Medexus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.3%-6.3%
TTM6.3%YOY4.2%+2.2%
TTM6.3%5Y-1.5%+7.8%
5Y-1.5%10Y-1.5%0.0%
1.2.2. Operating Ratio

Measures how efficient Medexus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.43 means that the operating costs are $1.43 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 1.434. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.364. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.434TTM1.364+0.070
TTM1.364YOY1.409-0.045
TTM1.3645Y1.453-0.089
5Y1.45310Y1.4530.000

1.3. Liquidity of Medexus Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Medexus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.11 means the company has $1.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 1.114. The company is just able to pay all its short-term debts.
  • The TTM is 0.928. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ1.114TTM0.928+0.187
TTM0.928YOY0.871+0.057
TTM0.9285Y1.038-0.110
5Y1.03810Y1.0380.000
1.3.2. Quick Ratio

Measures if Medexus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.33 means the company can pay off $0.33 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.334. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.417. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.334TTM0.417-0.083
TTM0.417YOY0.414+0.003
TTM0.4175Y0.535-0.118
5Y0.53510Y0.5350.000

1.4. Solvency of Medexus Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Medexus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Medexus to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.82 means that Medexus assets are financed with 81.6% credit (debt) and the remaining percentage (100% - 81.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.816. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.852. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.816TTM0.852-0.037
TTM0.852YOY0.880-0.027
TTM0.8525Y0.865-0.013
5Y0.86510Y0.8650.000
1.4.2. Debt to Equity Ratio

Measures if Medexus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 442.5% means that company has $4.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 4.425. The company is unable to pay all its debts with equity. -1
  • The TTM is 5.899. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.425TTM5.899-1.474
TTM5.899YOY7.368-1.469
TTM5.8995Y7.956-2.057
5Y7.95610Y7.9560.000

2. Market Valuation of Medexus Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Medexus generates.

  • Above 15 is considered overpriced but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -20.55 means the investor is paying $-20.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Medexus Pharmaceuticals Inc:

  • The EOD is -12.895. Based on the earnings, the company is expensive. -2
  • The MRQ is -20.548. Based on the earnings, the company is expensive. -2
  • The TTM is -4.804. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.895MRQ-20.548+7.654
MRQ-20.548TTM-4.804-15.744
TTM-4.804YOY-4.140-0.664
TTM-4.8045Y-4.498-0.306
5Y-4.49810Y-4.4980.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Medexus Pharmaceuticals Inc:

  • The EOD is 1.244. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 1.982. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 1.932. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.244MRQ1.982-0.738
MRQ1.982TTM1.932+0.050
TTM1.932YOY1.477+0.455
TTM1.9325Y-10.875+12.807
5Y-10.87510Y-10.8750.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Medexus is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Medexus Pharmaceuticals Inc:

  • The EOD is 0.932. Based on the equity, the company is cheap. +2
  • The MRQ is 1.485. Based on the equity, the company is underpriced. +1
  • The TTM is 1.675. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.932MRQ1.485-0.553
MRQ1.485TTM1.675-0.190
TTM1.675YOY2.130-0.456
TTM1.6755Y4.732-3.057
5Y4.73210Y4.7320.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Medexus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4400.199+121%-0.109+125%0.104+323%0.104+323%
Book Value Per Share--1.6641.357+23%0.953+75%1.084+53%1.084+53%
Current Ratio--1.1140.928+20%0.871+28%1.038+7%1.038+7%
Debt To Asset Ratio--0.8160.852-4%0.880-7%0.865-6%0.865-6%
Debt To Equity Ratio--4.4255.899-25%7.368-40%7.956-44%7.956-44%
Dividend Per Share----0%-0%-0%-0%
Eps---0.0300.083-136%-0.154+411%-0.133+344%-0.133+344%
Free Cash Flow Per Share--0.3120.292+7%-0.047+115%-0.002+101%-0.002+101%
Free Cash Flow To Equity Per Share---0.5410.032-1802%0.013-4414%0.079-782%0.079-782%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.910--------
Intrinsic Value_10Y_min--0.759--------
Intrinsic Value_1Y_max--0.021--------
Intrinsic Value_1Y_min--0.021--------
Intrinsic Value_3Y_max--0.117--------
Intrinsic Value_3Y_min--0.111--------
Intrinsic Value_5Y_max--0.278--------
Intrinsic Value_5Y_min--0.253--------
Market Cap37910210.000-59%60411786.11054908667.028+10%49772437.000+21%83937487.132-28%83937487.132-28%
Net Profit Margin---0.0210.051-142%-0.118+458%-0.104+391%-0.104+391%
Operating Margin---0.063-100%0.042-100%-0.0150%-0.0150%
Operating Ratio--1.4341.364+5%1.409+2%1.453-1%1.453-1%
Pb Ratio0.932-59%1.4851.675-11%2.130-30%4.732-69%4.732-69%
Pe Ratio-12.895+37%-20.548-4.804-77%-4.140-80%-4.498-78%-4.498-78%
Price Per Share1.550-59%2.4702.245+10%2.035+21%3.432-28%3.432-28%
Price To Free Cash Flow Ratio1.244-59%1.9821.932+3%1.477+34%-10.875+649%-10.875+649%
Price To Total Gains Ratio3.522-59%5.61218.290-69%-53.636+1056%-16.513+394%-16.513+394%
Quick Ratio--0.3340.417-20%0.414-19%0.535-38%0.535-38%
Return On Assets---0.0030.009-136%-0.019+483%-0.015+351%-0.015+351%
Return On Equity---0.0180.066-127%-0.159+780%-0.284+1474%-0.284+1474%
Total Gains Per Share--0.4400.199+121%-0.109+125%0.104+323%0.104+323%
Usd Book Value--29556588.97224115085.167+23%16929400.675+75%19263199.146+53%19263199.146+53%
Usd Book Value Change Per Share--0.3200.144+121%-0.079+125%0.076+323%0.076+323%
Usd Book Value Per Share--1.2080.986+23%0.692+75%0.788+53%0.788+53%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.0220.060-136%-0.112+411%-0.097+344%-0.097+344%
Usd Free Cash Flow--5535986.5085186800.434+7%-843595.560+115%-44302.450+101%-44302.450+101%
Usd Free Cash Flow Per Share--0.2260.212+7%-0.034+115%-0.002+101%-0.002+101%
Usd Free Cash Flow To Equity Per Share---0.3930.023-1802%0.009-4414%0.058-782%0.058-782%
Usd Market Cap27537976.544-59%43883121.43039885655.729+10%36154698.237+21%60972190.653-28%60972190.653-28%
Usd Price Per Share1.126-59%1.7941.631+10%1.478+21%2.493-28%2.493-28%
Usd Profit---533902.2571469730.931-136%-2730000.209+411%-2042256.464+283%-2042256.464+283%
Usd Revenue--25206385.37928925954.424-13%24926936.538+1%23425096.970+8%23425096.970+8%
Usd Total Gains Per Share--0.3200.144+121%-0.079+125%0.076+323%0.076+323%
 EOD+3 -5MRQTTM+18 -15YOY+26 -75Y+25 -710Y+25 -7

3.2. Fundamental Score

Let's check the fundamental score of Medexus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-12.895
Price to Book Ratio (EOD)Between0-10.932
Net Profit Margin (MRQ)Greater than0-0.021
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.334
Current Ratio (MRQ)Greater than11.114
Debt to Asset Ratio (MRQ)Less than10.816
Debt to Equity Ratio (MRQ)Less than14.425
Return on Equity (MRQ)Greater than0.15-0.018
Return on Assets (MRQ)Greater than0.05-0.003
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Medexus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.613
Ma 20Greater thanMa 501.586
Ma 50Greater thanMa 1001.678
Ma 100Greater thanMa 2001.927
OpenGreater thanClose1.510
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Working Capital  -53,56939,080-14,489-757-15,246-4,758-20,00530,46910,465



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets160,377
Total Liabilities130,815
Total Stockholder Equity29,562
 As reported
Total Liabilities 130,815
Total Stockholder Equity+ 29,562
Total Assets = 160,377

Assets

Total Assets160,377
Total Current Assets74,080
Long-term Assets86,297
Total Current Assets
Cash And Cash Equivalents 8,213
Net Receivables 22,227
Inventory 27,461
Other Current Assets 2,346
Total Current Assets  (as reported)74,080
Total Current Assets  (calculated)60,247
+/- 13,833
Long-term Assets
Property Plant Equipment 843
Goodwill 10,396
Intangible Assets 66,391
Long-term Assets  (as reported)86,297
Long-term Assets  (calculated)77,630
+/- 8,667

Liabilities & Shareholders' Equity

Total Current Liabilities66,477
Long-term Liabilities64,338
Total Stockholder Equity29,562
Total Current Liabilities
Short Long Term Debt 15,078
Accounts payable 43,354
Other Current Liabilities 2,747
Total Current Liabilities  (as reported)66,477
Total Current Liabilities  (calculated)61,179
+/- 5,298
Long-term Liabilities
Long term Debt 37,210
Long-term Liabilities  (as reported)64,338
Long-term Liabilities  (calculated)37,210
+/- 27,128
Total Stockholder Equity
Total Stockholder Equity (as reported)29,562
Total Stockholder Equity (calculated)0
+/- 29,562
Other
Capital Stock76,390
Common Stock Shares Outstanding 24,458
Net Debt 44,075
Net Invested Capital 81,850
Net Working Capital 7,603
Property Plant and Equipment Gross 1,916



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
122,773
125,249
121,589
138,049
148,513
142,970
137,210
138,131
139,225
136,399
142,308
146,320
161,329
166,874
166,178
160,377
160,377166,178166,874161,329146,320142,308136,399139,225138,131137,210142,970148,513138,049121,589125,249122,773
   > Total Current Assets 
39,732
59,365
54,836
72,677
58,571
47,886
43,918
46,595
49,111
48,385
56,686
61,886
72,969
79,503
79,479
74,080
74,08079,47979,50372,96961,88656,68648,38549,11146,59543,91847,88658,57172,67754,83659,36539,732
       Cash And Cash Equivalents 
5,233
7,484
6,403
9,351
18,704
10,199
8,137
9,571
10,018
7,285
9,647
9,273
13,069
15,782
19,501
8,213
8,21319,50115,78213,0699,2739,6477,28510,0189,5718,13710,19918,7049,3516,4037,4845,233
       Net Receivables 
14,739
22,780
19,242
33,310
18,829
17,037
14,083
14,689
14,407
14,715
17,017
20,323
22,381
25,946
22,659
22,227
22,22722,65925,94622,38120,32317,01714,71514,40714,68914,08317,03718,82933,31019,24222,78014,739
       Inventory 
14,084
19,754
19,061
16,737
14,667
13,081
14,408
16,176
21,351
21,979
23,758
22,404
22,848
25,003
24,851
27,461
27,46124,85125,00322,84822,40423,75821,97921,35116,17614,40813,08114,66716,73719,06119,75414,084
       Other Current Assets 
1,113
1,996
2,133
1,825
1,665
1,402
1,344
1,511
1,280
1,103
1,084
1,176
2,295
2,314
2,246
2,346
2,3462,2462,3142,2951,1761,0841,1031,2801,5111,3441,4021,6651,8252,1331,9961,113
   > Long-term Assets 
82,767
81,784
80,625
81,076
89,942
95,084
93,292
91,536
90,114
88,014
85,622
84,434
88,360
87,371
86,699
86,297
86,29786,69987,37188,36084,43485,62288,01490,11491,53693,29295,08489,94281,07680,62581,78482,767
       Property Plant Equipment 
1,099
1,392
1,282
1,110
795
1,407
1,336
1,252
1,221
1,125
1,021
953
899
875
894
843
8438948758999531,0211,1251,2211,2521,3361,4077951,1101,2821,3921,099
       Goodwill 
10,058
10,226
10,317
10,572
10,653
10,730
10,585
10,611
10,686
10,527
10,221
10,278
10,282
10,390
10,286
10,396
10,39610,28610,39010,28210,27810,22110,52710,68610,61110,58510,73010,65310,57210,31710,22610,058
       Intangible Assets 
69,765
68,424
67,239
67,518
76,362
80,815
79,268
77,927
76,565
74,811
72,936
71,618
70,373
69,172
67,602
66,391
66,39167,60269,17270,37371,61872,93674,81176,56577,92779,26880,81576,36267,51867,23968,42469,765
       Other Assets 
2,119
2,888
2,827
2,698
2,132
2,132
2,103
1,746
1,642
1,551
1,444
1,585
6,806
6,934
7,917
0
07,9176,9346,8061,5851,4441,5511,6421,7462,1032,1322,1322,6982,8272,8882,119
> Total Liabilities 
98,497
104,987
102,997
133,743
130,495
131,497
113,220
114,989
121,433
118,836
125,361
130,892
138,881
144,147
144,437
130,815
130,815144,437144,147138,881130,892125,361118,836121,433114,989113,220131,497130,495133,743102,997104,98798,497
   > Total Current Liabilities 
34,160
49,600
43,961
61,239
39,937
42,299
43,075
46,639
48,108
49,703
64,752
100,806
83,496
90,580
94,013
66,477
66,47794,01390,58083,496100,80664,75249,70348,10846,63943,07542,29939,93761,23943,96149,60034,160
       Short Long Term Debt 
10,195
9,999
10,833
17,025
10,569
16,375
12,860
18,231
15,046
19,559
29,698
65,177
42,706
47,483
48,358
15,078
15,07848,35847,48342,70665,17729,69819,55915,04618,23112,86016,37510,56917,02510,8339,99910,195
       Accounts payable 
8,906
32,033
27,365
35,866
14,855
23,319
26,926
24,307
12,046
25,421
28,875
27,683
33,415
34,846
34,783
43,354
43,35434,78334,84633,41527,68328,87525,42112,04624,30726,92623,31914,85535,86627,36532,0338,906
       Other Current Liabilities 
0
3,191
1,863
2,834
1,938
1,947
3,289
4,101
3,888
4,723
6,179
7,946
7,375
8,251
3,516
2,747
2,7473,5168,2517,3757,9466,1794,7233,8884,1013,2891,9471,9382,8341,8633,1910
   > Long-term Liabilities 
64,360
68,671
70,154
85,719
90,558
89,198
70,145
68,350
73,325
69,133
60,609
30,086
55,385
53,567
50,424
64,338
64,33850,42453,56755,38530,08660,60969,13373,32568,35070,14589,19890,55885,71970,15468,67164,360
       Long term Debt Total 
0
0
0
33,761
34,303
35,331
34,532
34,766
39,816
37,948
30,871
484
27,377
25,440
23,730
0
023,73025,44027,37748430,87137,94839,81634,76634,53235,33134,30333,761000
       Long term Debt 
28,606
29,931
31,268
33,545
34,303
35,331
34,532
34,766
39,816
37,948
30,871
484
27,377
25,440
23,730
37,210
37,21023,73025,44027,37748430,87137,94839,81634,76634,53235,33134,30333,54531,26829,93128,606
       Other Liabilities 
0
52,911
52,052
66,530
56,255
53,867
35,613
33,584
33,509
31,185
29,738
29,602
28,008
28,127
0
0
0028,12728,00829,60229,73831,18533,50933,58435,61353,86756,25566,53052,05252,9110
> Total Stockholder Equity
24,276
20,262
18,592
4,306
18,018
11,473
23,990
23,142
17,792
17,563
16,947
15,428
22,448
22,727
21,741
29,562
29,56221,74122,72722,44815,42816,94717,56317,79223,14223,99011,47318,0184,30618,59220,26224,276
   Common Stock
44,761
59,835
59,835
60,203
66,688
66,752
67,776
68,668
68,686
68,689
68,797
68,962
69,014
69,117
69,204
0
069,20469,11769,01468,96268,79768,68968,68668,66867,77666,75266,68860,20359,83559,83544,761
   Retained Earnings -65,004-64,470-63,377-64,028-70,884-69,377-66,647-65,249-59,962-58,812-68,957-62,370-63,618-46,552-44,525-34,106
   Capital Surplus 
7,041
9,795
10,219
10,155
9,497
10,081
10,696
10,135
10,384
10,684
10,835
10,960
11,307
11,465
10,913
0
010,91311,46511,30710,96010,83510,68410,38410,13510,69610,0819,49710,15510,2199,7957,041
   Treasury Stock0000000000000000
   Other Stockholders Equity 
6,580
2,569
1,385
-1,249
4,203
3,597
4,330
4,301
3,971
4,837
6,692
6,390
6,155
5,522
6,094
0
06,0945,5226,1556,3906,6924,8373,9714,3014,3303,5974,203-1,2491,3852,5696,580



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue108,096
Cost of Revenue-48,058
Gross Profit60,03860,038
 
Operating Income (+$)
Gross Profit60,038
Operating Expense-99,607
Operating Income7,614-39,569
 
Operating Expense (+$)
Research Development2,943
Selling General Administrative48,253
Selling And Marketing Expenses0
Operating Expense99,60751,196
 
Net Interest Income (+$)
Interest Income12,655
Interest Expense-13,606
Other Finance Cost-12,655
Net Interest Income-13,606
 
Pretax Income (+$)
Operating Income7,614
Net Interest Income-13,606
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,0417,538
EBIT - interestExpense = -5,117
-5,041
14,827
Interest Expense13,606
Earnings Before Interest and Taxes (EBIT)8,4898,565
Earnings Before Interest and Taxes (EBITDA)14,646
 
After tax Income (+$)
Income Before Tax-5,041
Tax Provision--6,262
Net Income From Continuing Ops1,2211,221
Net Income1,221
Net Income Applicable To Common Shares1,221
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net7613,606
 

Technical Analysis of Medexus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Medexus. The general trend of Medexus is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Medexus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Medexus Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.76 < 1.87 < 2.28.

The bearish price targets are: 1.48 > 1.44 > 1.44.

Tweet this
Medexus Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Medexus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Medexus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Medexus Pharmaceuticals Inc. The current macd is -0.04621153.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Medexus price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Medexus. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Medexus price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Medexus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartMedexus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Medexus Pharmaceuticals Inc. The current adx is 14.43.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Medexus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Medexus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Medexus Pharmaceuticals Inc. The current sar is 1.69733362.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Medexus Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Medexus Pharmaceuticals Inc. The current rsi is 43.61. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Medexus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartMedexus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Medexus Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Medexus price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Medexus Pharmaceuticals Inc Daily Stochastic Oscillator ChartMedexus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Medexus Pharmaceuticals Inc. The current cci is -94.02332362.

Medexus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartMedexus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Medexus Pharmaceuticals Inc. The current cmo is -10.34270096.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Medexus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartMedexus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Medexus Pharmaceuticals Inc. The current willr is -68.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Medexus is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Medexus Pharmaceuticals Inc Daily Williams %R ChartMedexus Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Medexus Pharmaceuticals Inc. The current atr is 0.09599207.

Medexus Pharmaceuticals Inc Daily Average True Range (ATR) ChartMedexus Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Medexus Pharmaceuticals Inc. The current obv is -2,059,961.

Medexus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartMedexus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Medexus Pharmaceuticals Inc. The current mfi is 30.63.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Medexus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartMedexus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Medexus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Medexus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Medexus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.613
Ma 20Greater thanMa 501.586
Ma 50Greater thanMa 1001.678
Ma 100Greater thanMa 2001.927
OpenGreater thanClose1.510
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Medexus with someone you think should read this too:
  • Are you bullish or bearish on Medexus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Medexus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Medexus Pharmaceuticals Inc

I send you an email if I find something interesting about Medexus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Medexus Pharmaceuticals Inc.

Receive notifications about Medexus Pharmaceuticals Inc in your mailbox!